What analysts say:
- Buy, sell, or hold?: Analysts are split on Balchem, as equal numbers rate the stock a buy, sell, and hold. Analysts don't like Balchem as much as competitor Innophos overall. Two out of three analysts rate Innophos a buy compared to one of three for Balchem. Analysts haven't adjusted their rating of Balchem for the past three months.
- Revenue forecasts: On average, analysts predict $77.4 million in revenue this quarter. That would represent a rise of 10.9% from the year-ago quarter.
- Wall Street earnings expectations: The average analyst estimate is earnings of $0.35 per share. Estimates range from $0.35 to $0.36.
What our community says:
CAPS All-Stars are strongly supporting the stock, with 100% assigning it an "outperform" rating. The community at large agrees with the All-Stars, with 97.8% giving it a rating of "outperform." Balchem has a bullish CAPS rating of five out of five stars that is about on par with the Fool community assessment.
Balchem's profit has risen year over year by an average of 25.9% over the past five quarters.
One final thing: If you want to keep tabs on Balchem movements, and for more analysis on the company, make sure you add it to your Watchlist.
Motley Fool newsletter services have recommended buying shares of Balchem.. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.Earnings estimates provided by Zacks.